pcDNA3.2 TDP-43 5F-L YFP Citations (4)

Originally described in: Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.
Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, Padmanabhan A, Clay-Falcone D, McCluskey L, Elman L, Juhr D, Gruber PJ, Rub U, Auburger G, Trojanowski JQ, Lee VM, Van Deerlin VM, Bonini NM, Gitler AD Nature. 2010 Aug 26;466(7310):1069-75. doi: 10.1038/nature09320. PubMed Journal

---

Articles Citing pcDNA3.2 TDP-43 5F-L YFP

Articles
TDP-43 misexpression causes defects in dendritic growth. Herzog JJ, Deshpande M, Shapiro L, Rodal AA, Paradis S. Sci Rep. 2017 Nov 15;7(1):15656. doi: 10.1038/s41598-017-15914-4. PubMed
RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43. Mann JR, Gleixner AM, Mauna JC, Gomes E, DeChellis-Marks MR, Needham PG, Copley KE, Hurtle B, Portz B, Pyles NJ, Guo L, Calder CB, Wills ZP, Pandey UB, Kofler JK, Brodsky JL, Thathiah A, Shorter J, Donnelly CJ. Neuron. 2019 Feb 27. pii: S0896-6273(19)30075-3. doi: 10.1016/j.neuron.2019.01.048. PubMed
Nuclear RNA binding regulates TDP-43 nuclear localization and passive nuclear export. Duan L, Zaepfel BL, Aksenova V, Dasso M, Rothstein JD, Kalab P, Hayes LR. Cell Rep. 2022 Jul 19;40(3):111106. doi: 10.1016/j.celrep.2022.111106. PubMed
RNA-binding properties orchestrate TDP-43 homeostasis through condensate formation in vivo. Scherer NM, Maurel C, Graus MS, McAlary L, Richter G, Radford RAW, Hogan A, Don EK, Lee A, Yerbury J, Francois M, Chung RS, Morsch M. Nucleic Acids Res. 2024 May 22;52(9):5301-5319. doi: 10.1093/nar/gkae112. PubMed

If you have published an article using this material, please email us at to have your article added to this page.